106 related articles for article (PubMed ID: 25201200)
1. Mdm2 and MdmX involvement in human cancer.
Berberich SJ
Subcell Biochem; 2014; 85():263-80. PubMed ID: 25201200
[TBL] [Abstract][Full Text] [Related]
2. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4.
Chandler DS; Singh RK; Caldwell LC; Bitler JL; Lozano G
Cancer Res; 2006 Oct; 66(19):9502-8. PubMed ID: 17018606
[TBL] [Abstract][Full Text] [Related]
3. Regulation of p53: a collaboration between Mdm2 and Mdmx.
Pei D; Zhang Y; Zheng J
Oncotarget; 2012 Mar; 3(3):228-35. PubMed ID: 22410433
[TBL] [Abstract][Full Text] [Related]
4. Effects of MdmX on Mdm2-mediated downregulation of pRB.
Uchida C; Miwa S; Isobe T; Kitagawa K; Hattori T; Oda T; Yasuda H; Kitagawa M
FEBS Lett; 2006 Mar; 580(7):1753-8. PubMed ID: 16510145
[TBL] [Abstract][Full Text] [Related]
5. Targeting p53-MDM2-MDMX loop for cancer therapy.
Zhang Q; Zeng SX; Lu H
Subcell Biochem; 2014; 85():281-319. PubMed ID: 25201201
[TBL] [Abstract][Full Text] [Related]
6. MDMX regulation of p53 response to ribosomal stress.
Gilkes DM; Chen L; Chen J
EMBO J; 2006 Nov; 25(23):5614-25. PubMed ID: 17110929
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
Ghosh M; Huang K; Berberich SJ
Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
[TBL] [Abstract][Full Text] [Related]
8. An essential function of the extreme C-terminus of MDM2 can be provided by MDMX.
Uldrijan S; Pannekoek WJ; Vousden KH
EMBO J; 2007 Jan; 26(1):102-12. PubMed ID: 17159902
[TBL] [Abstract][Full Text] [Related]
9. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.
Okamoto K; Taya Y; Nakagama H
FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542
[TBL] [Abstract][Full Text] [Related]
10. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L
Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108
[TBL] [Abstract][Full Text] [Related]
11. MdmX inhibits Smad transactivation.
Kadakia M; Brown TL; McGorry MM; Berberich SJ
Oncogene; 2002 Dec; 21(57):8776-85. PubMed ID: 12483531
[TBL] [Abstract][Full Text] [Related]
12. A site-directed mutagenesis study of the MdmX RING domain.
Egorova O; Mis M; Sheng Y
Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
[TBL] [Abstract][Full Text] [Related]
13. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
[TBL] [Abstract][Full Text] [Related]
14. Mdmx as an essential regulator of p53 activity.
Marine JC; Jochemsen AG
Biochem Biophys Res Commun; 2005 Jun; 331(3):750-60. PubMed ID: 15865931
[TBL] [Abstract][Full Text] [Related]
15. Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradation.
Bergamaschi D; Samuels Y; Zhong S; Lu X
Oncogene; 2005 May; 24(23):3836-41. PubMed ID: 15782125
[TBL] [Abstract][Full Text] [Related]
16. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
17. Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development.
Steinman HA; Hoover KM; Keeler ML; Sands AT; Jones SN
Oncogene; 2005 Nov; 24(53):7935-40. PubMed ID: 16027727
[TBL] [Abstract][Full Text] [Related]
18. MDMX: a novel p53-binding protein with some functional properties of MDM2.
Shvarts A; Steegenga WT; Riteco N; van Laar T; Dekker P; Bazuine M; van Ham RC; van der Houven van Oordt W; Hateboer G; van der Eb AJ; Jochemsen AG
EMBO J; 1996 Oct; 15(19):5349-57. PubMed ID: 8895579
[TBL] [Abstract][Full Text] [Related]
19. [Study of the molecular mechanisms controlling activity of protein p53 in the development of new strategies in cancer therapeutics].
Marine Ch
Bull Mem Acad R Med Belg; 2009; 164(5-6):175-80; discussion 180-1. PubMed ID: 20666148
[TBL] [Abstract][Full Text] [Related]
20. MDM2 is a central node in the p53 pathway: 12 years and counting.
Bond GL; Hu W; Levine AJ
Curr Cancer Drug Targets; 2005 Feb; 5(1):3-8. PubMed ID: 15720184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]